Immatics unveils promising, early-stage data for a top contender in the race to develop TCRs. Now it has to live up to expectations
Immatics has scored a significant advance in its quest to develop cell therapies for solid tumors.
Tuesday morning the biotech — based in Germany with a big operation in Houston — took the wraps off a set of promising preliminary data from an early-stage study of its TCR therapy, IMA203.
Examining the drug’s effect on 16 cancer patients who had already endured a median of 4 previous systemic treatments, researchers concluded that half — 8 — of them had registered an objective response against a range of solid tumor types. Three of the patients who didn’t respond were on the very lowest dose, the least likely to respond, while investigators tracked encouraging dose responses at higher levels.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.